The following list of published research is intended to serve as a resource for study of inflammatory myopathies.

2013

• Mazen M. Dimachkie, M.D. and Richard J. Barohn, M.D.   Inclusion Body Myositis . Semin Neurol 2012; 32:237-245.  DOI  Http://dx.doi.org/10.1055/s-0032-1329197.  ISSN 0271-8235.
• Jana Zschuntzsch, Joachim Voss, Kim Creus, Stephan Sehmisch, Raghavan Raju, Marinos C. Dalakas, and Jens Schmidt.  Provision o fan Explanation for the Inefficacy of Immunotherapy in Sporadic Inclusion Body Myositis .  Arthritis & Rheumatism.  Vol. 64, No. 12, December 2012, pp 4094-4103.  DOI 10.1002/art.37692.

2012

• Bruno Gualano, Carlos Ugrinowitsch, Manoel Neves Jr., Fernanda R. Lima, Ana Lucia S. Pinto, Gilberto Laurentino, Valmor A.A. Tricoli, Antonio H. Lancha Jr., and Hamilton Roschel.  Vascular Occlusion Training for Inclusion Body Myositis:  A Novel Therapeutic Approach.  Journal of Visualized Experiments.  J Vis Exp. 2010; (40):  1894.   

2011

• K.A. Bernhardt, T.H. Oh, K.R. Kaufman.  Gait patterns of patients with inclusion body myositis . Gait Posture (2011), doi 10.1016/i.gaitpost.2010.12.021.

2010

• Valerie Askansas, MD, PhD; W. King Engel, MD; Anna Nogalska, PhD.  Inclusion Body Myositis: A Degenerative Muscle Fiber Associated with Intra-Muscle Fiber Multi-Protein Aggregates, Proteasome Inhibition, Endoplasmic Reticulum Stress and Decreased Lysosomal Degradation . Brain Pathology. 2009; 19: 493-506.
• D. Hilton, A. Miller, M. Parton, J. Holton, C. Sewry, M.G. Hanna.  MRC Centre for Neuromuscular Diseases, IBM Work Shop, London. Neuromuscular Disorders. 2008 June.
• A A Amato & R J Barohn.  Inclusion Body Myositis: Old and New Concepts. Journal of Neurology, Neurosurgery, and Psychiatry. 2009; 80; 1186-1193.
• Mike Recher, Ulrike Sahrbacher, Juliane Bremer, Borge Arndt, Urs Steiner, Adriano Fontana.  Treatment of IBM with Low-Dose IVIG. Rheumatol Int. DOI 10.1007/s00296-009-1290-z.
• Anna Nogalska, Chiara Terracciano, Carla D'Agostino, W. King Engel, Valerie Askansas.  p62/SQSTM1 in IBM. Acta Neuropathol. 2009. 118:407-413.
• Chiara Terracciano, Anna Nogalska, W. King Engel and Valerie Askansas.  Lithium and IBM. Journal Of Neurochemistry. 2010. 112: 389-396.
• Wolfgang Utz, Saskia Schmidt, Jeanette Schulz-Menger, Friedrich Luft, Simone Spuler.  Cardiac Involvement in Sporadic Inclusion-Body Myositis. Circulation Journal of The American Heart Association. 2010;121;706-708. DOI: 10.1161/CIRCULATIONAHA.109.866178
• Steven A. Greenberg.  Theories of the Pathogenesis of Inclusion Body Myositis. Curr Rheumatol Rep. 16 April 2010. DOI 10.1007/s11926-010-0102-5.
• Bruno Gualano, Manoel Neves Jr, Fernanda Rodrigues Lima, Ana Lucia De Sa Pinot, Gilberto Laurentino, Claudia Borges, Luciana Baptista, Guilherme Giannini Artioli, Marcelo Saldanha Aoki, Anslmo Moriscot, Antonio Herbert Lancha Jr, Eloisa Bonfa and Carlos Ugrinowitsch.  Resistance Training with Vascular Occlusion in Inclusion Body Myositis: A Case Study. Medicine & Science In Sports & Exercise. 2010. DOI:10.1249/MSS.0b013e3181b18fb8.
• R Sadjadi, M R Rose and Muscle Study Group.  What determines quality of life in inclusion body myositis? Journal of Neurology, Neurosurgrey & Psychiatry. July 2, 2010. DOI: 10.1136/jnnp.2009.183863.
• Thomas E. Lloyd.  Novel therapeutic approaches for inclusion body myositis. Current Opinion in Rheumatology 2010. 22:000-00.

2006-2009

• Janaiah Kota, et al.  Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates. Sci Transl Med 1, 6ra15 (2009); DOL: 10.1126/scitranslmed.3000112.
• Askanas A, Engel K. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathologica, October 2008.
• Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet. 2007 July; 6:620-31.
• Dalakas MC.  Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies. Nature Clinical Practice, Neurology 2 (8): 437-447, 2006
• Drs. Kitazawa, Vasilevko, Cribbs and LaFerla of the University of California.  Live vaccination reduces muscle impairment in mice with IBM-like muscle disease
•  Effects of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009 June; 132(6): 1536-1544, published online 2009 March 22. doi: 10. 1093/brain/awp 104.

2001-2005

• Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome. Neuron 43,3:321-332, 2004. (See EurekAlert summary article entitled "Immune therapy 'untangles' Alzheimers' Disease")
• Dalakas MC, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56: 323-327, 2001
• The Muscle Study Group. Randomized pilot trial of BINF1a (Avonex) in patients with inclusion body myositis. Neurology 57: 1566-1570, 2001
• Walter MC, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol 247: 22-28, 2000

1996-2000

• Dalakas MC, et al. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 48: 712-716, 1997

1991-1995

• Leff RL, et al. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 72 (4): 225-235, 1993

1980-1990